<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="7016">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03015584</url>
  </required_header>
  <id_info>
    <org_study_id>1040524</org_study_id>
    <nct_id>NCT03015584</nct_id>
  </id_info>
  <brief_title>Systems Biology Approach to Cognitive Impairment After SepsiS</brief_title>
  <acronym>CASS</acronym>
  <official_title>Systems Biology Approach to Cognitive Impairment After SepsiS (CASS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intermountain Health Care, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Intermountain Health Care, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will use systems biology techniques, especially RNA-seq, to understand cognitive
      impairment after sepsis requiring an intensive care unit (ICU) admission.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Hayling Sentence Completion test</measure>
    <time_frame>6 months</time_frame>
    <description>Measures executive function. 6-month Hayling Sentence Completion test is the prespecified primary outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Wechsler Memory Scale Logical Memory 1 assessment</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wechsler Memory Scale Logical Memory 1 assessment</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wechsler Memory Scale Logical Memory 2 assessment</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wechsler Memory Scale Logical Memory 2 assessment</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Digit Span memory assessment</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Digit Span memory assessment</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Verbal Fluency test</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Verbal Fluency test</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wechsler Similarities assessment</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wechsler Similarities assessment</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQol five dimensions questionnaire (EQ-5D-3L)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQol five dimensions questionnaire (EQ-5D-3L)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>36-item short form survey (SF-36)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>36-item short form survey (SF-36)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Anxiety and Depression Scale (HADS)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Anxiety and Depression Scale (HADS)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of Event Scale-Revised (IES-R)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of Event Scale-Revised (IES-R)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Performance Inventory (FPI)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Performance Inventory (FPI)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Assessment of Chronic Illness Therapy (FACIT)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Assessment of Chronic Illness Therapy (FACIT)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activities of Daily Living/Instrumental Activities of Daily Living (ADL/IADL)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activities of Daily Living/Instrumental Activities of Daily Living (ADL/IADL)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hayling Sentence Completion test</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>90-day mortality</measure>
    <time_frame>90 days</time_frame>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Sepsis</condition>
  <condition>Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>Septic patients admitted to the ICU</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood for RNA-seq and whole exome sequencing
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with sepsis or septic shock, admitted to the ICU.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria

        - Either SEPSIS or SEPTIC SHOCK

        A. SEPSIS:

        PRESENCE OF

          1. Suspected or confirmed infection AND

          2. Organ dysfunction as defined by a SOFA &gt;= 2 above baseline (if no baseline data
             available, SOFA assumed to be 0)

        OR

        B. SEPTIC SHOCK:

        AFTER INTRAVENOUS INFUSION OF 20ML/KG CRYSTALLOID OR EQUIVALENT, PRESENCE OF

          1. Suspected or confirmed infection AND

          2. Lactate &gt; 2 mmol/L AND

          3. Receiving vasopressors

        Enrollment within 48 hours of ICU admission.

        Must live within 200 miles of Intermountain Medical Center

        Subject is at least 18 years of age or older

        Must speak English

        Exclusion Criteria:

          -  Onset of sepsis or septic shock &gt;24 hours after hospital admission

          -  Patients transferred from another hospital except for directly from an emergency room

          -  Patients transferred to the ICU &gt;48 hours after admission to Intermountain Medical
             Center (must have been admitted with diagnosis of sepsis)

          -  Prior traumatic brain injury, stroke, or intracranial hemorrhage

          -  DNR/DNI order before study enrollment

          -  Primary diagnosis of stroke or intracranial hemorrhage

          -  Known preexisting dementia or substantial cognitive impairment of any cause
             (established from both chart review, report and/or score â‰¥3 on IQ Code screening.

          -  Prior cardiac surgery (coronary artery bypass grafting or surgical valve replacement
             or repair)

          -  Known schizophrenia or other psychotic thought disorder

          -  Known pregnancy

          -  Primary diagnosis of drug overdose

          -  Attending physician deems aggressive care unsuitable

          -  Enrolled in another study if that study involves drug interventions

          -  Not expected to survive 48 hours

          -  Has a terminal condition independent of the acute illness that is expected to lead to
             death within 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samuel Brown, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Intermountain Health Care, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne Haroldsen</last_name>
    <phone>(801) 507-4607</phone>
    <email>Anne.Haroldsen@imail.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mardee Merrill</last_name>
    <phone>(801) 507-4608</phone>
    <email>Mardee.Merrill@imail.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Intermountain Medical Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mardee Merill</last_name>
      <phone>801-507-4608</phone>
      <email>Mardee.Merill@imail.org</email>
    </contact>
    <contact_backup>
      <last_name>Valerie Aston</last_name>
      <phone>(801) 507-4606</phone>
      <email>Valerie.Aston@imail.org</email>
    </contact_backup>
    <investigator>
      <last_name>Angela Presson, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ramona Hopkins, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Carlquist, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>James Orme, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Colin Grissom, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Russ Miller, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ellie Hirshberg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emily Wilson, MStat</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ithan Peltan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jorie Butler, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthew Rondina, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sarah Beesley, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 9, 2017</lastchanged_date>
  <firstreceived_date>December 8, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cognition Disorders</mesh_term>
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
